Millennium Management
INTS icon

Millennium Management’s Intensity Therapeutics INTS Stock Holding History

Millennium Management’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-993
Closed -$101K – 6289
2023
Q3 		$101K Buy
+993
New +$137K ﹤0.01% 5335

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HWM
Hohimer Wealth Management Seattle, Washington $847M AUM 29.89% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management's INTS Position: Q4 2023 in Review

Millennium Management sold out of Intensity Therapeutics (INTS) in Q4 2023, closing a stake of 993 shares — an estimated $101K sold.

Millennium Management first reported a position in INTS in Q3 2023 and held it in 1 quarter. The position peaked at $101K in Q3 2023. 16 funds tracked by Wall St. Rank hold INTS as of Q4 2023.

  • Millennium Management reported no remaining Intensity Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Millennium Management sold 993 Intensity Therapeutics shares in Q4 2023, an estimated $101K.
  • Millennium Management first reported a position in Intensity Therapeutics in Q3 2023 and held it in 1 quarter.
  • Millennium Management's Intensity Therapeutics position peaked at $101K in Q3 2023.
  • 16 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q4 2023.

Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.